Abstract Number: 1960 • ACR Convergence 2023
From Clinical Amyopathy to Severe Oropharyngeal Dysphagia in Pure Dermatomyositis: A Greater Extent of Muscle Weakness Is Associated with a Higher Cancer Prevalence
Background/Purpose: The risk of cancer is increased in patients with pure dermatomyositis (DM), i.e. patients with a DM rash and without an anti-MDA-5 syndrome, a…Abstract Number: 1138 • ACR Convergence 2023
Nailfold Capillaroscopy Findings in Patients with Idiopathic Inflammatory Myopathies and Its Association to Autoantibodies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired muscle diseases, which have distinct clinical, pathological and histological features. Autoantibodies are clinically useful…Abstract Number: 1965 • ACR Convergence 2023
Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Idiopathic Inflammatory Myopathies: Results from the COVAD Study
Background/Purpose: Disease activity assessment is key in the management of patients with idiopathic inflammatory myopathies (IIM). However, patients' perception of disease may differ from clinicians.…Abstract Number: 1158 • ACR Convergence 2023
Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection
Background/Purpose: Dermatomyositis (DM) is an autoimmune disorder part of the group of idiopathic inflammatory myopathies. It is characterized by proximal muscle weakness and skin involvement.…Abstract Number: 1966 • ACR Convergence 2023
Investigating Esophageal Involvement in Anti-Synthetase Syndrome: How to Discover the Submerged?
Background/Purpose: Anti-synthetase syndrome (ASS) is an idiopathic inflammatory myopathy, typically characterized from the triad interstitial lung disease (ILD), myositis and arthritis, together with anti-aminoacyl tRNA…Abstract Number: 1164 • ACR Convergence 2023
Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study
Background/Purpose: Immune-mediated myopathies (IMM) are a heterogeneous group of diseases characterized by inflammation and muscle weakness; among their differential diagnoses are the dysferlinopathies, which are…Abstract Number: 1969 • ACR Convergence 2023
Multimorbidity and PROMIS Health Outcomes in Patients with Idiopathic Inflammatory Myopathies: Analysis from the COVAD Study
Background/Purpose: Comorbidities have a profound impact on the quality of life (QoL), though global data on the burden of comorbidities and its impact on health…Abstract Number: 1168 • ACR Convergence 2023
Evaluation of Agreement Between Functional and Radiological Changes in Idiopathic Inflammatory Myositis (IIM) Associated Interstitial Lung Disease (ILD)
Background/Purpose: ILD is a major cause of morbidity and mortality in IIM. The diagnosis and progression of ILD often relies on high resolution computed tomography…Abstract Number: 1971 • ACR Convergence 2023
Muscle Pathology in Patients with Primary Biliary Cholangitis
Background/Purpose: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that primarily affects middle-aged women. It is characterized by elevated serum alkaline phosphatase levels,…Abstract Number: 0169 • ACR Convergence 2023
Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective
Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) is a subgroup of immune-mediated myopathies (IMM). The diagnosis of IMNM relied on the presence of proximal muscle weakness, high…Abstract Number: 1172 • ACR Convergence 2023
Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse
Background/Purpose: Our aim was to explore whether maintenance of remission in patients with idiopathic inflammatory myopathy (IIM) depends on glucocorticoids (GCs) after achieving remission. Therefor…Abstract Number: 2461 • ACR Convergence 2023
Transcriptional Derepression of CHD4/NuRD-regulated Genes in the Muscle of Patients with Dermatomyositis and anti-Mi2 Autoantibodies
Background/Purpose: Myositis is a heterogeneous family of diseases including dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome (AS), and inclusion body myositis (IBM). Myositis-specific autoantibodies…Abstract Number: 0290 • ACR Convergence 2023
Patient-reported Quality of Life and Working Status Outcomes in Ambulatory Patients with Idiopathic Inflammatory Myopathy
Background/Purpose: To investigate the health-related quality of life (HR-QoL), work productivity and activity impairment, and associated factors among patients with idiopathic inflammatory myopathy (IIM). Methods:…Abstract Number: 1174 • ACR Convergence 2023
Anti-HMGCR Immune-mediated Necrotising Myopathy: Calculation of Incidence and Confirmation of Low Malignancy Risk in Two Independent Cohorts. a Retrospective Case Review
Background/Purpose: Immune-mediated necrotising myopathy (IMNM) is a rare complication of statin therapy, associated with the development of anti-HMGCR antibodies directed against the enzymatic target of…Abstract Number: 2462 • ACR Convergence 2023
Mitochondrial-Mediated Neutrophil Activation in Dermatomyositis (DM) and Inclusion Body Myositis (IBM): Insights into Pathogenesis and Therapeutic Implications
Background/Purpose: Dermatomyositis (DM) and inclusion body myositis (IBM) are characterized by muscle weakness and inflammation, with emerging evidence of mitochondrial and neutrophil involvement. Prior work…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 9
- Next Page »